Apyx Medical (NASDAQ:APYX) will release first-quarter fiscal 2026 results before markets open on May 7, 2026. Management will host an 8:00 a.m. ET conference call and live webcast the same day; replay will be archived on the company’s Investor Relations website. Apyx markets Renuvion, J-Plasma, and the FDA-cleared AYON Body Contouring System; the company cites more than 90 clinical documents supporting Renuvion and J-Plasma.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – APYX
-0.78%
-0.78%Session close to close
In the Apr 23 session, APYX declined 0.78%, reflecting a mild negative market reaction.
This announcement sets the timetable for Apyx Medical’s Q1 FY2026 results and conference call on May...
Analysis
This announcement sets the timetable for Apyx Medical’s Q1 FY2026 results and conference call on May 7, giving investors clarity on when new financial data will arrive. Recent filings showed 2025 revenue of $52.8 million and cash of $31.7 million, alongside guidance for higher 2026 revenue. Investors may focus on how upcoming results track against that outlook and on ongoing adoption of the Renuvion and AYON platforms.
Key Figures
Loss from operations:$6.4 millionCash used in operations:$8.0 millionCash & equivalents:$31.7 million+5 more
8 metrics
Loss from operations$6.4 millionFull year 2025 loss from operations (10-K)
Cash used in operations$8.0 millionCash used in operating activities for 2025 (10-K)
Cash & equivalents$31.7 millionCash and cash equivalents at Dec 31, 2025 (10-K/8-K)
2025 revenue$52.8 millionFull year 2025 revenue (8-K)
2026 revenue outlook (low)$57.5 millionLower end of 2026 revenue guidance range (8-K)
Registered direct offering$7.0 millionRegistered direct offering completed in 2024 (10-K)
Announced Q4 2025 earnings release date and conference call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior earnings date scheduling news was followed by a negative price reaction, suggesting investors have previously used these dates as de-risking opportunities.
Recent Company History
Over recent months, Apyx Medical highlighted product and investor-relations milestones, including conference participation and an award for Renuvion, alongside detailed Q4 and full-year 2025 results on Mar 10, 2026. That earnings release showed revenue growth and improved profitability metrics. A prior earnings date announcement on Feb 25, 2026 was followed by a -3.39% move, suggesting that mere scheduling updates have not been strong positive catalysts by themselves.
Key Terms
helium plasma platform technology, fda-cleared, body contouring system, electrosurgical, +1 more
5 terms
helium plasma platform technologymedical
"including its Helium Plasma Platform Technology products marketed and sold as Renuvion"
A helium plasma platform uses a stream of ionized helium gas energized by radiofrequency energy to heat, cut or seal human tissue during surgical and aesthetic procedures. Think of it as a focused, high‑heat tool that lets clinicians tighten skin, remove tissue, or control bleeding with minimal cutting—similar to a precision blowtorch compared with a scalpel. Investors care because the technology’s safety profile, regulatory approvals, and adoption by doctors drive device sales, recurring disposable use and potential market growth.
fda-clearedregulatory
"The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body"
FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.
body contouring systemmedical
"The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body"
A body contouring system is a medical or cosmetic device that reshapes or firms areas of the body by reducing fat, tightening skin, or remodeling tissue using technologies such as lasers, ultrasound, radiofrequency, or cooling. Investors care because these devices drive sales, recurring treatment revenue, and potential margins tied to consumables and maintenance, and their commercial value hinges on safety, regulatory approvals, and patient demand—think of the system as a specialized tool used in aesthetic procedures that must meet medical standards.
electrosurgicalmedical
"integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion"
Electrosurgical describes tools and procedures that use controlled electric current to cut, seal, or stop bleeding in body tissues during medical procedures, similar to using a heated knife or a precise spark instead of a scalpel. For investors, electrosurgical products matter because they drive sales, device adoption, regulatory reviews, and liability risk in the surgical devices market—factors that affect revenue, profit margins, and company valuations.
oem agreementstechnical
"leverages its deep expertise and decades of experience in unique waveforms through OEM agreements"
OEM agreements are contracts where one company makes products or components that another company sells under its own brand, like a bakery baking cakes that a café sells with the café’s name. For investors, these deals matter because they influence cost structure, product quality, supply reliability and how much control a brand has over manufacturing; strong OEM partnerships can speed growth but can also create dependence on outside suppliers.
CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th.
Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 7th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Investor Relations Contact: Jeremy Feffer Managing Director LifeSci Advisors OP: 212-915-2568 jfeffer@lifesciadvisors.com
FAQ
When will Apyx Medical (APYX) release Q1 fiscal 2026 results and hold the earnings call?
Apyx Medical will release Q1 fiscal 2026 results before markets open on May 7, 2026. According to the company, management will host a conference call at 8:00 a.m. ET that morning with a follow-up Q&A and a live webcast.
How can investors access the Apyx Medical (APYX) May 7, 2026 earnings call and webcast?
Investors can dial the provided phone numbers with access code 81537 or use the live webcast link on the Investor Relations site. According to the company, the webcast will also be archived for later access.
What products does Apyx Medical (APYX) highlight ahead of its May 7, 2026 results?
Apyx Medical highlights Renuvion, J-Plasma, and the AYON Body Contouring System. According to the company, AYON is FDA-cleared and Renuvion/J-Plasma are supported by more than 90 clinical documents.
Will the Apyx Medical (APYX) May 7, 2026 call include a Q&A session for investors?
Yes, the management call scheduled for 8:00 a.m. ET on May 7, 2026 will include a question-and-answer session. According to the company, participants on the call may ask questions following the formal remarks.
Where can I find archived materials and the webcast for Apyx Medical (APYX) earnings on May 7, 2026?
Archived webcast and related materials will be available via the company’s Investor Relations section. According to the company, the earnings webcast will be posted there and kept for future reference after the live event.
